HK1033667A1 - Bisulfate salt of hiv protease inhibitor - Google Patents

Bisulfate salt of hiv protease inhibitor

Info

Publication number
HK1033667A1
HK1033667A1 HK01103011A HK01103011A HK1033667A1 HK 1033667 A1 HK1033667 A1 HK 1033667A1 HK 01103011 A HK01103011 A HK 01103011A HK 01103011 A HK01103011 A HK 01103011A HK 1033667 A1 HK1033667 A1 HK 1033667A1
Authority
HK
Hong Kong
Prior art keywords
protease inhibitor
hiv protease
bisulfate salt
bisulfate
salt
Prior art date
Application number
HK01103011A
Other languages
English (en)
Inventor
Janak Singh
Madhusudhan Pudipeddi
Mark D Lindrud
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22104737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1033667(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HK1033667A1 publication Critical patent/HK1033667A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK01103011A 1998-01-20 2001-04-26 Bisulfate salt of hiv protease inhibitor HK1033667A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7196898P 1998-01-20 1998-01-20
PCT/US1998/027382 WO1999036404A1 (en) 1998-01-20 1998-12-22 Bisulfate salt of hiv protease inhibitor

Publications (1)

Publication Number Publication Date
HK1033667A1 true HK1033667A1 (en) 2001-09-14

Family

ID=22104737

Family Applications (2)

Application Number Title Priority Date Filing Date
HK01103011A HK1033667A1 (en) 1998-01-20 2001-04-26 Bisulfate salt of hiv protease inhibitor
HK01104126A HK1033458A1 (en) 1998-01-20 2001-06-15 Bisulfate salt of hiv protease inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK01104126A HK1033458A1 (en) 1998-01-20 2001-06-15 Bisulfate salt of hiv protease inhibitor

Country Status (39)

Country Link
US (1) US6087383A (de)
EP (1) EP1056722B1 (de)
JP (2) JP4860037B2 (de)
KR (1) KR100559283B1 (de)
CN (1) CN1116282C (de)
AR (1) AR014417A1 (de)
AT (1) ATE219057T1 (de)
AU (1) AU735875B2 (de)
BG (1) BG64774B1 (de)
BR (1) BR9814736A (de)
CA (1) CA2317736C (de)
CO (1) CO4970820A1 (de)
CZ (1) CZ293507B6 (de)
DE (1) DE69806067T2 (de)
DK (1) DK1056722T3 (de)
EE (1) EE04434B1 (de)
EG (1) EG23936A (de)
ES (1) ES2178300T3 (de)
GE (1) GEP20033026B (de)
HK (2) HK1033667A1 (de)
HU (1) HU227196B1 (de)
IL (2) IL137384A0 (de)
LT (1) LT4780B (de)
LV (1) LV12522B (de)
MY (1) MY114838A (de)
NO (1) NO315605B1 (de)
NZ (1) NZ504417A (de)
PE (1) PE20000185A1 (de)
PL (1) PL190744B1 (de)
PT (1) PT1056722E (de)
RO (1) RO118869B1 (de)
RU (1) RU2186070C2 (de)
SK (1) SK283975B6 (de)
TR (1) TR200001876T2 (de)
TW (1) TW531531B (de)
UA (1) UA59432C2 (de)
UY (1) UY25345A1 (de)
WO (1) WO1999036404A1 (de)
ZA (1) ZA9956B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03010733A (es) 2001-05-22 2004-07-01 Upjohn Co Compuestos de etilamina aza-hidroxilados.
US7157561B2 (en) * 2001-07-13 2007-01-02 Roche Diagnostics Operations, Inc. Methods of inhibiting transmission of a costimulatory signal of lymphocytes
US7193065B2 (en) * 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
KR20090053867A (ko) * 2003-01-14 2009-05-27 길리애드 사이언시즈, 인코포레이티드 복합 항바이러스 치료를 위한 조성물 및 방법
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
CN1980666B (zh) * 2004-05-04 2011-03-30 布里斯托尔-迈尔斯斯奎布公司 制备阿扎那韦硫酸氢盐的方法和新的形式
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US7829720B2 (en) 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
TWI354569B (en) * 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
US7642049B2 (en) * 2006-06-30 2010-01-05 Bristol-Myers Squibb Company Method for identifying HIV-1 protease inhibitors with reduced metabolic affects through detection of human resistin polymorphisms
US20090306112A1 (en) * 2006-07-21 2009-12-10 Gilead Sciences, Inc. Antiviral protease inhibitors
BG66056B1 (bg) * 2006-10-05 2010-12-30 Красимир ДЕЧЕВ Метод и инсталация за производство на трисезонна добавка към дизелово гориво
ES2356334T3 (es) * 2007-06-12 2011-04-07 Concert Pharmaceuticals, Inc. Derivados de azapéptidos como inhibidores de la proteasa vih.
ES2359770T3 (es) * 2007-06-22 2011-05-26 Bristol-Myers Squibb Company Composiciones en comprimidos que contienen atazanavir.
ES2360336T3 (es) * 2007-06-22 2011-06-03 Bristol-Myers Squibb Company Composiciones en comprimidos que contienen atazanavir.
PL2170292T3 (pl) * 2007-06-22 2014-06-30 Bristol Myers Squibb Holdings Ireland Tabletkowane kompozycje zawierające atazanawir
EP2178513B1 (de) * 2007-06-22 2011-03-30 Bristol-Myers Squibb Company Tablettierte atazanavirhaltige zusammensetzungen
AU2008270630B2 (en) * 2007-06-29 2014-01-16 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
EA200971096A1 (ru) * 2007-06-29 2010-08-30 Джилид Сайэнс, Инк. Терапевтические композиции и их применение
WO2009136365A1 (en) * 2008-05-08 2009-11-12 Ranbaxy Laboratories Limited Process for the preparation of 3,4-epoxy-2-amino-1-substituted butane derivatives and intermediate compounds thereof
WO2010070611A1 (en) 2008-12-18 2010-06-24 Ranbaxy Laboratories Limited Atazanavir formulations
US8552036B2 (en) 2009-01-12 2013-10-08 Hetero Research Foundation Polymorph of atazanavir sulfate
WO2010138338A1 (en) 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Hiv protease inhibitors
EP2272830A1 (de) 2009-06-18 2011-01-12 Esteve Química, S.A. Herstellungsverfahren für ein antivirales heterozyklisches Azahexan-Derivat
WO2011027324A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Polymorphic forms of atazanavir sulfate
JP6122639B2 (ja) 2009-10-26 2017-04-26 メルク・シャープ・エンド・ドーム・コーポレイション インテグラーゼ阻害剤を含有する固形医薬組成物
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
ES2969969T3 (es) 2010-01-27 2024-05-23 Viiv Healthcare Co Combinaciones de dolutegravir y lamivudina para el tratamiento de la infección por VIH
WO2011107843A2 (en) 2010-03-01 2011-09-09 Lupin Limited Process for the preparation of atazanavir sulfate substantially free of diastereomers
CN102917695A (zh) 2010-04-09 2013-02-06 百时美施贵宝公司 具有改进的pH效应的阿扎那韦硫酸盐制剂
EP2621472A1 (de) 2010-09-28 2013-08-07 Ratiopharm GmbH Trockenverarbeitung von atazanavir
US20140343290A1 (en) 2011-07-27 2014-11-20 Rakesh Kumar Singh Process for the preparation of atazanavir or its bisulfate salt
US8461347B2 (en) 2011-08-05 2013-06-11 Scinopharm Taiwan, Ltd. Process for preparing form A of atazanavir sulfate
US9133157B2 (en) 2011-10-26 2015-09-15 Merck Canada Inc. HIV protease inhibitors
WO2014030173A2 (en) * 2012-08-24 2014-02-27 Laurus Labs Private Limited An improved process for the preparation of atazanavir bisulfate
WO2014036690A1 (zh) * 2012-09-04 2014-03-13 上海迪赛诺化学制药有限公司 制备阿扎那韦硫酸氢盐a型结晶的方法
EP2956439B1 (de) 2013-02-12 2019-01-09 Cipla Limited Verfahren zur herstellung von atazanavirsulfat
CN104250225A (zh) * 2013-06-28 2014-12-31 上海威智医药科技有限公司 阿扎那韦磷酸盐及其制备和应用
CN104250223B (zh) * 2013-06-28 2017-04-12 上海威智医药科技有限公司 阿扎那韦氢溴酸盐及其制备和应用
CN104250224A (zh) * 2013-06-28 2014-12-31 上海威智医药科技有限公司 阿扎那韦富马酸盐及其制备和应用
CN105859611A (zh) * 2016-04-18 2016-08-17 上海现代制药海门有限公司 一种阿扎那韦硫酸氢盐a型结晶的制备方法
CN109251165B (zh) * 2018-10-02 2022-09-23 国药集团川抗制药有限公司 阿扎那韦达二4-氨基苯磺酸盐及其制备方法
CN111349042B (zh) * 2018-12-20 2023-07-14 陕西理工大学 一种阿扎那韦单晶及其制备方法
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives

Also Published As

Publication number Publication date
EP1056722A1 (de) 2000-12-06
SK283975B6 (sk) 2004-06-08
RU2186070C2 (ru) 2002-07-27
JP2002509136A (ja) 2002-03-26
CZ293507B6 (cs) 2004-05-12
LT4780B (lt) 2001-04-25
CZ20002564A3 (cs) 2000-10-11
HUP0101389A2 (hu) 2001-08-28
CN1116282C (zh) 2003-07-30
PL190744B1 (pl) 2006-01-31
JP4860037B2 (ja) 2012-01-25
JP2009102357A (ja) 2009-05-14
ZA9956B (en) 2000-07-05
CA2317736A1 (en) 1999-07-22
US6087383A (en) 2000-07-11
CN1283188A (zh) 2001-02-07
IL137384A0 (en) 2001-07-24
DE69806067D1 (de) 2002-07-18
IL137384A (en) 2006-08-01
UA59432C2 (uk) 2003-09-15
AU2010199A (en) 1999-08-02
AU735875B2 (en) 2001-07-19
HUP0101389A3 (en) 2003-07-28
BR9814736A (pt) 2000-10-24
EG23936A (en) 2008-01-14
BG104618A (en) 2001-02-28
TR200001876T2 (tr) 2000-11-21
CA2317736C (en) 2004-11-02
PT1056722E (pt) 2002-09-30
SK10622000A3 (sk) 2001-02-12
ES2178300T3 (es) 2002-12-16
ATE219057T1 (de) 2002-06-15
EE200000798A (et) 2002-06-17
BG64774B1 (bg) 2006-03-31
HU227196B1 (en) 2010-10-28
MY114838A (en) 2003-01-31
LV12522B (en) 2000-10-20
NO315605B1 (no) 2003-09-29
LT2000067A (en) 2000-11-27
PL342019A1 (en) 2001-05-07
RO118869B1 (ro) 2003-12-30
TW531531B (en) 2003-05-11
GEP20033026B (en) 2003-07-25
EE04434B1 (et) 2005-02-15
CO4970820A1 (es) 2000-11-07
EP1056722A4 (de) 2001-01-10
UY25345A1 (es) 2000-12-29
KR20010034221A (ko) 2001-04-25
EP1056722B1 (de) 2002-06-12
NO20003692L (no) 2000-07-19
WO1999036404A1 (en) 1999-07-22
KR100559283B1 (ko) 2006-03-15
DK1056722T3 (da) 2002-09-30
LV12522A (en) 2000-08-20
DE69806067T2 (de) 2003-01-23
AR014417A1 (es) 2001-02-28
HK1033458A1 (en) 2001-08-31
NO20003692D0 (no) 2000-07-19
PE20000185A1 (es) 2000-05-14
NZ504417A (en) 2001-09-28

Similar Documents

Publication Publication Date Title
HK1033458A1 (en) Bisulfate salt of hiv protease inhibitor
PL349192A1 (en) Protease inhibitors
IL142398A0 (en) Serine protease inhibitor
ZA983629B (en) Serine protease inhibitors
PL343112A1 (en) Quinolones as serine protease inhibitors
EP1093367A4 (de) Proteaseinhibitoren
IL132630A0 (en) Protease inhibitors
PL337725A1 (en) Inhibitors of proteases
IL139187A0 (en) Cysteine protease inhibitors
EP1067894A4 (de) Protheaseinhibitoren
EP1079821A4 (de) Protease inhibitoren
GB9800817D0 (en) Serine protease inhibitors
EP1086083A4 (de) Proteaseinhibitoren
EP1140897A4 (de) Protease inhibitoren
PL342602A1 (en) Method of synthesising inhibitors of hiv protease
ZA984514B (en) Hiv protease inhibitor
IL132998A0 (en) Vif-derived hiv protease inhibitors
AU2001280634A1 (en) Salt forms of an hiv protease inhibitor
EP1195163A4 (de) Serinprotease-inhibitoren
GB9714320D0 (en) Hiv protease inhibitor
PL335672A1 (en) Hiv protease inhibitors
GB9814307D0 (en) Inhibition of serine proteases
SI1066276T1 (en) Process for the synthesis of hiv protease inhibitors
HU0900220D0 (en) Hiv protease inhibitors

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20181221